Research Triangle Park, NC, January 9, 2019: The Carolina Longevity Institute, LLC (CLI), announced that Brian Huber has joined as Chief Operations and Scientific Officer, effective January 9, 2019. CLI is an emerging portfolio of companies on a mission to enable people to live longer and to age healthier with better quality of life through innovative research, and world class interventions that promote healthy aging.
With more than 35 years of experience and demonstrated success in the biopharmaceutical drug development and investment sectors, Brian Huber will lead the scientific and operational activities at CLI. Preceding his position at CLI, Huber worked as managing director and VP at Quintiles/IQVIA. His prior experience over the course of two decades was as VP in Drug Discovery at GlaxoSmithKline (GSK) and senior staff fellow at the National Cancer Institute of the National Institutes of Health. Huber’s experience has ranged from managing drug discovery and clinical drug development portfolios to achieving maximal patient value and company ROI. He has engaged in developing and managing key partnerships for financial growth, clinical delivery and execution, and profitability. His pas work has involved identifying, structuring, and managing innovative clinical investments involving biopharmaceutical companies and third-party syndicated capital sources.
Huber holds a Ph.D. in pharmacology from The George Washington University and a B.S. and M.S. from Villanova University. He is also Board Certified in Clinical Pharmacology and has completed residency programs in Advanced Leadership from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and at the London Business School. He holds adjunct academic positions at Duke University and The George Washington University.
“I am thrilled Dr. Brian Huber has joined the Carolina Longevity Institute team,” said CLI’s CEO and Portfolio Manager Michael Holder. “Dr. Huber brings a wealth of experience, knowledge and strategically significant relationships in the healthcare and longevity arenas to CLI, with a particular focus on the pharmaceutical industry, clinical studies, patient-centric values and economic success. Throughout his distinguished career, he has demonstrated a vigorous work ethic with a strong commitment to detail and excellence on the clinical and investment fronts that are encompassed in – and are an ideal fit for – CLI’s strategic investment efforts and mission to improve and extend human life.”
“I’ve spent my entire career in the drug discovery and clinical development fields,” Huber said. “What excites me most about CLI is that our business strategy ranges from addressing the diseases associated with aging, such as cancer and Alzheimer’s, to maintenance of health throughout the aging process. I’m excited about the breadth and the depth of what CLI wants to accomplish in health care, and the visionary, entrepreneurial culture. I’m also extremely enthusiastic about working with Michael to make CLI a great success. We’re starting from scratch, but the playing field is wide open. That is a once in a lifetime opportunity.”
About Carolina Longevity Institute
CLI’s mission is to significantly extend human life expectancy while simultaneously improving human healthspan (the number of years a person lives disease free). CLI is deploying resources nationally and internationally to carry out that mission on a number of fronts, including, but not limited to, investing in leading longevity therapy research and clinical trials. CLI is also building a portfolio of longevity and healthspan related companies in a variety of industries including, but not limited to, longevity clinics, supplements and nutraceuticals, genetics and precision medicine-related diagnostic labs, health products, artificial intelligence, and telemedicine in the U.S. and internationally.
Carolina Longevity Institute
Erin Masercola, Ph.D.
Source: Carolina Longevity Institute